• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 455404 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1414766122 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1414766122 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Analyst Rating Flashback: Illumina Up 6.4% Since Upgraded 7 Days Ago (ILMN)

Published on Fri, 03/08/2013 - 10:11
By Mallory Stone

Illumina was upgraded from Neutral to Buy by UBS one week ago. Illumina shares are selling at $53.33, 6.4% above the $50.13 price point of one week ago.

Illumina share prices have moved between a 52-week high of $79.40 and a 52-week low of $25.57 and are now trading 109% above that low price at $53.47 per share. Over the last five market days, the 200-day moving average (MA) has gone up 0.4% while the 50-day MA has declined 0.2%.

Illumina has overhead space with shares priced $53.47, or 2.3% below the average consensus analyst price target of $54.73. The stock should discover initial support at its 50-day moving average (MA) of $51.64 and subsequent support at its 200-day MA of $46.98.

Illumina, Inc. develops, manufactures and markets integrated systems for the large scale analysis of genetic variation and biological function. The Company provides a comprehensive line of products and services that currently serve the sequencing, genotyping and gene expression markets for genomic research centers, pharmaceutical companies, academic institutions and biotechnology companies.

By Mallory Stone
mstone@fnno.com

Latest News from FNNO

Exxon Mobil (XOM) Breaks Through Resista...

Shares of Exxon Mobil (NYSE:XOM) opened today above their pivot of $94.11 and have alre ...

Analyst Rating Flashback: Equinix Up 4.9...

A week ago, Cowen and Company downgraded Equinix from Outperform to Market Perform. Th ...

NIC Down 2.1% Since Raymond James Downgr...

NIC was downgraded from Strong Buy to Market Perform by Raymond James one week ago. Th ...

Plexus Up 7.0% Since Raymond James Upgra...

Raymond James upgraded Plexus (NASDAQ:PLXS) from Market Perform to Outperform a week ag ...

NPS Pharmaceuticals Down 2.1% Since Gold...

One week ago NPS Pharmaceuticals (NASDAQ:NPSP) was downgraded from Buy to Neutral at Go ...

Check Point Software Technologies In Ret...

Needham upgraded Check Point Software Technologies (NASDAQ:CHKP) from Hold to Buy a wee ...

Analyst Rating Flashback: Amazon.com Dow...

One week ago Amazon.com (NASDAQ:AMZN) was downgraded from Buy to Neutral at Janney Mont ...

Amazon.com In Retrospect: Shares Down 4....

One week ago Amazon.com (NASDAQ:AMZN) was downgraded from Outperform to Market Perform ...